Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Kidney Dis ; 31(4): 674-80, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9531185

ABSTRACT

Radiocontrast-induced nephropathy (RCIN) is a common cause of hospital-acquired acute renal failure and is associated with a high mortality rate. RCIN is potentially preventable, because administration of the radiocontrast agent is predictable, and a high-risk population has been identified. This multicenter, prospective, randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy of intravenous atrial natriuretic peptide (anaritide, ANP 4-28) to prevent RCIN. Patients with stable chronic renal failure (serum creatinine greater than 1.8 mg/dL or serum creatinine between 1.5 and 1.8 mg/dL with estimated creatinine clearance of < or = 65 mL/min) were assigned to receive either placebo or one of three doses of anaritide (0.01 microg/kg/min, 0.05 microg/kg/min, or 0.1 microg/kg/min) for 30 minutes before and continuing for 30 minutes after radiocontrast administration. All patients were given intravenous 0.45% saline for 12 hours before the radiocontrast procedure and continuing for 12 hours after the last dose of radiocontrast. Both ionic and nonionic radiocontrast agents were administered. RCIN was defined as either an absolute increase of serum creatinine of > or = 0.5 mg/dL or a percent increase of > or = 25% over baseline. Of the 247 patients who completed the study, 50% had diabetes mellitus. There were no statistical differences in baseline serum creatinine, change in serum creatinine, or the incidence of RCIN. The incidence of RCIN was placebo, 19%; anaritide (0.01), 23%; anaritide (0.05), 23%; anaritide (0.1), 25%. Patients with diabetes mellitus had a significantly greater incidence of RCIN: placebo, 26% versus 9%; anaritide (0.01), 33% versus 13%; anaritide (0.05), 26% versus 21%; anaritide (0.1), 39% versus 8% (diabetic v nondiabetic, P < 0.002). There was no effect in the diabetic or nondiabetic groups by anaritide on the incidence of RCIN. Comparison of the highest-risk group of patients, defined as patients with diabetes mellitus and a baseline serum creatinine > or = 1.8 mg/dL, with the lowest-risk group, defined as patients without diabetes mellitus and a baseline serum creatinine of 1.8 mg/dL or less, did not show a beneficial effect of anaritide administration. In conclusion, administration of intravenous anaritide before and during a radiocontrast study did not reduce the incidence of RCIN in patients with preexisting chronic renal failure, with or without diabetes mellitus.


Subject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/prevention & control , Atrial Natriuretic Factor/administration & dosage , Contrast Media/adverse effects , Acute Kidney Injury/blood , Adolescent , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Infusions, Intravenous , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/diagnostic imaging , Male , Middle Aged , Prospective Studies , Radiography , Risk Factors , Time Factors
2.
Arch Intern Med ; 157(16): 1833-8, 1997 Sep 08.
Article in English | MEDLINE | ID: mdl-9290542

ABSTRACT

BACKGROUND: Acute tubular necrosis (ATN) is the most common type of acute renal failure in hospitalized patients and is associated with a high morbidity and mortality. The cause of ATN can be divided into nephrotoxic, ischemic, or mixed. OBJECTIVE: To test the hypothesis that the cause of ATN affects its clinical outcome. METHODS: The study compares clinical outcomes of patients enrolled in the placebo arm of a multicenter, randomized, double-blinded, placebo-controlled trial of anaritide (Auriculin, synthetic atrial natriuretic peptide, Scios, Mountain View, Calif) in patients with well-defined ATN. Patients were divided prospectively into groups according to the cause of ATN: pure nephrotoxic, pure ischemic, or mixed nephrotoxic and ischemic. Outcomes of interest were dialysis-free survival and all-cause mortality on day 14 and day 21. The causal groups were compared with respect to the prevalence of several comorbidities suspected of affecting the clinical outcomes. RESULTS: Mortality was 10% in the nephrotoxic group and 30% in the ischemic group on day 21. Dialysis-free survival was 66% in the nephrotoxic group and 41% in the ischemic group on day 21. Outcomes in the mixed and ischemic groups were similar. Compared with the nephrotoxic group, there was a significantly higher prevalence of cardiogenic shock, hypotension, sepsis, and respiratory failure and a tendency toward a higher prevalence of acute hepatic dysfunction in the ischemic group. Diabetes mellitus was more prevalent in the nephrotoxic group. Among patients with ischemic ATN, dialysis-free survival improved significantly and mortality tended to decline with advancing age. CONCLUSIONS: Among patients with ATN, those in whom renal ischemia was causative had significantly higher mortality and lower dialysis-free survival than those whose ATN was purely nephrotoxic in origin. This difference in clinical outcomes was associated with a higher prevalence of serious commorbidities in the ischemic ATN group. Advancing age was associated with improved dialysis-free survival and a tendency toward reduced mortality in patients with ischemic ATN.


Subject(s)
Kidney Tubular Necrosis, Acute/etiology , Adult , Aged , Atrial Natriuretic Factor/therapeutic use , Diuretics/therapeutic use , Double-Blind Method , Female , Humans , Ischemia/complications , Kidney Tubular Necrosis, Acute/drug therapy , Kidney Tubular Necrosis, Acute/mortality , Male , Middle Aged , Natriuresis/drug effects , Peptide Fragments/therapeutic use , Prognosis , Prospective Studies , Randomized Controlled Trials as Topic , Renal Dialysis , Risk Factors , Survival Analysis
3.
N Engl J Med ; 336(12): 828-34, 1997 Mar 20.
Article in English | MEDLINE | ID: mdl-9062091

ABSTRACT

BACKGROUND: Atrial natriuretic peptide, a hormone synthesized by the cardiac atria, increases the glomerular filtration rate by dilating afferent arterioles while constricting efferent arterioles. It has been shown to improve glomerular filtration, urinary output, and renal histopathology in laboratory animals with acute renal dysfunction. Anaritide is a 25-amino-acid synthetic form of atrial natriuretic peptide. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial of anaritide in 504 critically ill patients with acute tubular necrosis. The patients received a 24-hour intravenous infusion of either anaritide (0.2 microgram per kilogram of body weight per minute) or placebo. The primary end point was dialysis-free survival for 21 days after treatment. Other end points included the need for dialysis, changes in the serum creatinine concentration, and mortality. RESULTS: The rate of dialysis-free survival was 47 percent in the placebo group and 43 percent in the anaritide group (P = 0.35). In the prospectively defined subgroup of 120 patients with oliguria (urinary output, < 400 ml per day), dialysis-free survival was 8 percent in the placebo group (5 of 60 patients) and 27 percent in the anaritide group (16 of 60 patients, P = 0.008). Anaritide-treated patients with oliguria who no longer had oliguria after treatment benefited the most. Conversely, among the 378 patients without oliguria, dialysis-free survival was 59 percent in the placebo group (116 of 195 patients) and 48 percent in the anaritide group (88 of 183 patients, P = 0.03). CONCLUSIONS: The administration of anaritide did not improve the overall rate of dialysis-free survival in critically ill patients with acute tubular necrosis. However, anaritide may improve dialysis-free survival in patients with oliguria and may worsen it in patients without oliguria who have acute tubular necrosis.


Subject(s)
Atrial Natriuretic Factor/therapeutic use , Diuretics/therapeutic use , Kidney Tubular Necrosis, Acute/drug therapy , Peptide Fragments/therapeutic use , Double-Blind Method , Female , Humans , Infusions, Intravenous , Kidney Tubular Necrosis, Acute/complications , Kidney Tubular Necrosis, Acute/mortality , Kidney Tubular Necrosis, Acute/therapy , Male , Middle Aged , Oliguria/etiology , Prospective Studies , Renal Dialysis , Survival Analysis , Treatment Outcome
4.
Arch Dermatol ; 125(12): 1662-5, 1989 Dec.
Article in English | MEDLINE | ID: mdl-2589861

ABSTRACT

The intrinsic potencies of two novel topical thiol ester corticosteroids, RS-85095 and RS-21314, were compared with the high potency corticosteroids clobetasol 17-propionate and fluocinonide, using human vasoconstriction assays. In these assays, four or five concentrations (0.03 to 3 mg/L) of the corticosteroids in 95% ethanol (alcohol, USP) were applied to predetermined sites on the forearm of volunteers and were occluded following evaporation of the alcohol. The responses were scored in terms of the presence or absence of vasoconstriction and the degree of vasoconstrictive intensity. No statistically significant difference was found in the intrinsic potencies of RS-85095, RS-21314, and clobetasol 17-propionate, and all three corticosteroids were significantly more potent than fluocinonide.


Subject(s)
Androstenols/pharmacology , Betamethasone/analogs & derivatives , Clobetasol/analogs & derivatives , Fluocinolone Acetonide/analogs & derivatives , Fluocinonide/pharmacology , Vasoconstriction/drug effects , Administration, Topical , Adult , Clobetasol/pharmacology , Drug Administration Schedule , Female , Humans , Male
5.
Ann Intern Med ; 99(5): 737-8, 1983 Nov.
Article in English | MEDLINE | ID: mdl-6638740
6.
J Histochem Cytochem ; 27(1): 268-72, 1979 Jan.
Article in English | MEDLINE | ID: mdl-374584

ABSTRACT

An effective method of graphically representing complex biological data is presented, and a statistical classification technique is outlined including an example involving exfoliated cervical cells.


Subject(s)
Cervix Uteri/cytology , Cytological Techniques , Optics and Photonics , Statistics as Topic , Computers , Diagnosis, Computer-Assisted , Diagnosis, Differential , Female , Humans , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Neoplasms/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...